This paper is a brief review which deals with research findings, clinical issues, and strategies in 
On the U.S. market, there are four categories of chemicals which have antidepressant or mood-stabilizing effects:
Heterocyclic Antidepressants Table 1 is a list of tricyclic antidepressants (TCAs) and second-generation antidepressants. Adapted from most updated literature,1-3 the list includes all currently available American heterocyclic antidepressants with putative action sites in the central neurotransmission. The TCAs are so designated due to their central struc tural formula, which has three rings or closed-chain structures. Having been introduced to the American market in the past decade, the second-generation anti depressants have monocyclic (bupropion), bicyclic (fluoxetine), tricyclic (amoxapine, clomipramine), and tetracyclic (maprotiline) rings in the central nucleus of the chemical structures.
The term "heterocyclic antidepressants" is often called "cyclic antidepressants" for simplification by many authors in American psychiatric literature. The term "TCA -like antidepressants" is also used for heterocyclic antidepressants to distinguish from monoamine oxidase inhibitor (MAOI) antidepressants, which also have 1 or 2 rings in each chemical structure.
The heterocyclic antidepressants can benefit 65-80% of depressed patients, but placebo can improve about only 20-40% of the control group.2 The half-lives of these agents are fairly long (20-160 hours), thus single daily dosage at bedtime is generally indicated.4 (The exceptions are fluoxetine and bupropion. The latter is recommended in divided doses whereas the former is to be administered in the morning.) Absorptions of hetero cyclic antidepressants are fairly well. It takes 5 to 20 days to achieve a steady state level of the agents. There are up to 36-fold differences in plasma levels among patients who have received the same dose. These differences seem to be largely genetically determined.2,4
The typical side effects of heterocyclic antidepressants include sedation, dry mouth, constipation, urinary reten tion, dizziness, orthostatic hypotension, weight gain, blurred vision, nausea, vomiting, tachycardia, palpitation of the heart, heart block, peculiar taste, etc.1,2 Not rarely, drug-induced sexual dysfunctions are also re ported in both males and female patients.5-7 Besides fluoxetine and bupropion, most heterocyclic antide pressants are implicated with patients' weight gain. Because of this characteristic, fluoxetine has enjoyed unprecedented popularity in publications for American lay public press.8
Monoamine oxidase inhibitors (MAOIs)
Monoamine oxidase inhibitor (MAOI) antidepress ants marketed in the U.S. include phenelzine, isocarbox azid, and tranylcypromine.1,2 The chemical distinction between hydrazine (phenelzine and isocarboxazid) and non-hydrazine (tranylcypromine) MAOIs do not bear much clinical significance. Most psychiatrists in the U.S. reserve MAOIs as second-line drugs in the pharmaco therapy of depression if (1) a couple of heterocyclic antidepressants do not work, (2) the depressed patients cannot tolerate the heterocyclic side effects, or (3) electroconvulsive therapy (ECT) is inappropriate or refused. MAOIs are often thought to be the drugs of choice for "atypical" depressed patients who overeat and/or oversleep.9 MAOIs have been underprescribed by American psychiatrists due to undue overemphasis on side effects in the literature.10 Recent clinical studies in treating phobia11 and post-traumatic stress syndrome12,13 have caused resurgence of interest in MAOIs, most by discovering the old wisdom in the literature about MAOIs. The knowledge of antidepressant effect and at least 80% reduction of the platelet MAO enzymatic activity has advanced the clinical practice to obtain op timal therapeutic MAOI dosage level. 14,15 Adapted from the 1990 physicians' desk reference (reference 1) Adapted from the 1990 physicians desk reference (reference 1)
The greatest concern for MAOI-medicated patients is the dietary and drug restrictions during MAOI therapy. TCAs. The augmentation effect of depression can be achieved in a couple of days when lithium reaches the serum level of 0.4-0.6mEq/1 instead of typical rec ommended therapeutic ranges of 0.5-1.5mEq/l.
The initial side effects are nausea, stomach cramps, being thirsty, muscle weakness, tremors of the hands, weight, etc. These side effects are usually transient but some of them may persist during the course of lithium therapy.1 Although the official recommended laboratory workups are many,17 regular blood tests for serum lithium levels as well as initial tests for creatinine, blood urea nitrogen, and thyroid profiles are done by a majority of practicing psychiatrists in the U.S.
Carbamazepine and other antiepileptic agents
The introduction of carbamazepine in psychiatric use is a Japanese contribution. Takezaki and Hanaoka first in 1971 discovered the usefulness of carbamazepine in affective disorders.22 Then, Okuma and associates in 1973 first reported in English that carbamazepine has antimanic and prophylactic effects on bipolar disorder. Ten years later, the psychiatric use of carbamazepine started to kindle the researchers' interest at the National Institute of Mental Health (NIMH)24,25 and comparative controlled studies of carbamazepine efficacy were pub lished. 24, 26 Carbamazepine is also shown to be especially ben eficial in treating acute episodes or preventing the re lapses of "rapid cycling patients" who are the bipolar disorder patients having four or more episodes of illnesses per year. 27 In a recent review of literature, Post and associates28 concluded that rapid cyclers often show in adequate response to lithium carbonate and vulnerable to antidepressant-induced switches of cycle acceleration. Kukopulos and co-workers29 also suggested that the use of antidepressants on the rapid cyclers contributes the non-response rate in mood stabilization when lithium carbonate is used. Although the clinical indication of carbamazepine for antimanic or antidepressant effect has never been formally included in the PDR,1 it is rather widely used in the U.S., especially if any patients who are refractory or intolerable to the lithium side effects, such as diarrhea, tremors of the hands, and facial acnes.
Usually, the carbamazepine antidepressant effects are achieved with 600-1600mg/day at serum levels of 8-12ng/ml. 25 The side effects of carbamazepine are relatively mild and tolerable. But, physicians are always alert to look of patients' fever, sore throat, and sub cutaneous bleedings, to obtain complete blood counts once a week in the first month, then once every two weeks in the next several months, and thereafter once a month as long as the patient continues to receive carbamazepine. 25 Beside using carbamazepine, American psychiatrists are assessing the antidepressant effects of sodium val proate, which was first introduced for psychiatric treat ment in Europe in 1966. 30 
Acute treatment of depression
Under the pressure for cost-containment in medical care resources by the American government and the third party payers, the indication of admitting a non suicidal depressive patient to inpatient service becomes stricter every day. The American psychiatrists would be amazed at the report of the patients' lengthy stay of 1 to 2 months in the Japanese psychiatric hospital. 31 The earlier research excitement attempting to differ entiate two types of norepinephrine or serotonin de pression,32 do not give any clinical validity. It also does not mean much clinically to dichotomize heterocyclic antidepressants by separating norepinephrine and sero tonin reuptake blockers as shown in Table 1 , since there is no discernible clinical characteristics of depression to justify the choice of one heterocyclic over another in terms of clinical efficacy. However, the medication neurotransmitter profiles can help the patient to predict what kind of side effects that patient will experience, although the data cannot help psychiatrists predict the treatment responses.
Heterocyclic antidepressants are the mainstay of treating depression in both outpatient and inpatient set tings. Thus, assessing the clinical response, interpreting the side effects of heterocyclics and compromising the patients' tolerance of side effects are daily routines in the clinic where acute depressive patients are attending.
ECT has a high recovery rate and is used for quick and effective treatment for severe depression . But this effective therapy has been unduly stigmatized by the of Depression in USA public and American civil libertarians. MAOIs are indi cated for those who are refractory to heterocyclic (s) and who have clinical features of or history of panic attacks . Depressed patients with mood-congruent psychotic fea tures need a combination of a heterocyclic and a low dose of a neoleptic agent.33,34 It is logical to prescribe amoxapine which has both antidepressive and anti psychotic properties for the treatment of psychotic depression.
Maintenance treatment of depression
Post at NIMH has long hypothesized that antidepress ant agents can suppress depressive symptoms without immediately correcting the underlying biological process of the depression.35 Thus, if the antidepressant, such as imipramine, is stopped before the whole episode of depression is over, the patient may have the risk of running the unfinished course of the depressive process. This concept has dictated the concept of maintenance treatment of depression, which means administering the antidepressant continuously after acute depressive symptoms have disappeared.
A collaborative project of NIHM in 1986 provided the first study-derived guidelines on the length of continued therapy, to prevent either the premature withdrawal of the drug and subsequent relapse or unnecessarily pro longed treatment. 36 The findings of the results indicate that withdrawal of maintenance therapy is safe only after the patient has been free of significant symptoms for 16-20 weeks. During the medication withdrawal, the physician should focus on mild as well as severe symptoms in the decision to terminate maintenance therapy. 36 Prophylactic treatment of depression Depression is notorious for the tendency to recur in its natural course.37,38 Angst and coworkers in Switzerland demonstrated that depressive cycle length decreased from about 3 years after the first episode, to 2 years after the second, and to 11/2 years after the third.39 They also found that there is a 70% risk probability of developing 2 or more depressive episodes in the subsequent 5 years after a patient has had two major depressive episodes within 5 years.
That lithium remains the mainstay for prophylactic treatment for most patients with bipolar disorders 17,41 and 10 to 15 percent of patients with unipolar disorders,41 has been officially approved by the American Psychiatric Association in 1975 and NIMH in 1985. The theoretical and practical aspects dealing with the issues of lithium maintenance have been recently detailed in a monograph. 42 The NIMH Conference Report in 198541 concluded that either a heterocyclic antidepressant or lithium is effective in the prophylaxis of recurrent mood disorders. The heterocyclic antidepressant is more effectively, easily, and popularly used than lithium in preventing depression.43 Thus, the heterocyclic antidepressant is mostly used for prophylactive treatment of depression. Mostly, American psychiatrists prescribe at a time only one antidepressant rather than polypharmacy which may be popular in Japan. 44 
Concluding Remarks
In a recent NIMH community survey on epidemiologic catchment areas, major depression is found to be a major psychiatric problem in the general population, especially for the female.45 In the U. S., depression is often called the common cold in psychiatry. Nishizono of Fukuoka University in 1989 also suggests that the Japanese have moved from Morita nervousness and hys teria (before World War II), and from the Era of Anxiety (after World War II) to the Era of Depression. 46 Thus, the needs to advance pharmacotherapy as the effective treatment method for depression are apparently urgent in both the East and the West. Exchanges in psychiatric knowledge can stimulate the progress on improving psychiatric care for the depressive sufferers.
